PMID- 32989915
OWN - NLM
STAT- MEDLINE
DCOM- 20210806
LR  - 20210806
IS  - 1759-7714 (Electronic)
IS  - 1759-7706 (Print)
IS  - 1759-7706 (Linking)
VI  - 11
IP  - 11
DP  - 2020 Nov
TI  - Detection of circulating genetically abnormal cells in peripheral blood for early 
      diagnosis of non-small cell lung cancer.
PG  - 3234-3242
LID - 10.1111/1759-7714.13654 [doi]
AB  - BACKGROUND: Circulating genetically abnormal cells (CACs) with specific 
      chromosome variations have been confirmed to be present in non-small cell lung 
      cancer (NSCLC). However, the diagnostic performance of CAC detection remains 
      unclear. This study aimed to evaluate the potential clinical application of the 
      CAC test for the early diagnosis of NSCLC. METHODS: In this prospective study, a 
      total of 339 participants (261 lung cancer patients and 78 healthy volunteers) 
      were enrolled. An antigen-independent fluorescence in situ hybridization was used 
      to enumerate the number of CACs in peripheral blood. RESULTS: Patients with 
      early-stage NSCLC were found to have a significantly higher number of CACs than 
      those of healthy participants (1.34 vs. 0.19; P < 0.001). The CAC test displayed 
      an area under the receiver operating characteristic (ROC) curve of 0.76139 for 
      discriminating stage I NSCLC from healthy participants with 67.2% sensitivity and 
      80.8% specificity, respectively. Compared with serum tumor markers, the 
      sensitivity of CAC assays for distinguishing early-stage NSCLC was higher (67.2% 
      vs. 48.7%, P < 0.001), especially in NSCLC patients with small nodules (65.4% vs. 
      36.5%, P = 0.003) and ground-glass nodules (pure GGNs: 66.7% vs. 40.9%, P = 
      0.003; mixed GGNs: 73.0% vs. 43.2%, P < 0.001). CONCLUSIONS: CAC detection in 
      early stage NSCLC was feasible. Our study showed that CACs could be used as a 
      promising noninvasive biomarker for the early diagnosis of NSCLC. KEY POINTS: 
      What this study adds: This study aimed to evaluate the potential clinical 
      application of the CAC test for the early diagnosis of NSCLC. Significant 
      findings of the study: CAC detection in early stage NSCLC was feasible. Our study 
      showed that CACs could be used as a promising noninvasive biomarker for the early 
      diagnosis of NSCLC.
CI  - (c) 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and 
      John Wiley & Sons Australia, Ltd.
FAU - Liu, Wei-Ran
AU  - Liu WR
AD  - Department of Anesthesiology, Tianjin Medical University Cancer Institute and 
      Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer 
      Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 
      China.
FAU - Zhang, Bin
AU  - Zhang B
AD  - Department of Lung Cancer, Tianjin Lung Cancer Center, Tianjin Medical University 
      Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key 
      Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center 
      for Cancer, Tianjin, China.
FAU - Chen, Chen
AU  - Chen C
AD  - Department of Lung Cancer, Tianjin Lung Cancer Center, Tianjin Medical University 
      Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key 
      Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center 
      for Cancer, Tianjin, China.
FAU - Li, Yue
AU  - Li Y
AD  - Department of Lung Cancer, Tianjin Lung Cancer Center, Tianjin Medical University 
      Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key 
      Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center 
      for Cancer, Tianjin, China.
FAU - Ye, Xin
AU  - Ye X
AD  - Joint Research Center of Liquid Biopsy in Guangdong, Hong kong, and Macao, 
      Zhuhai, China.
AD  - Zhuhai Sanmed Biotech Ltd., Zhuhai, China.
AD  - Guangdong Postdoctoral Innovation Practice Bases, School of Biology and 
      Biological Engineering, South China University of Technology, China.
FAU - Tang, Dong-Jiang
AU  - Tang DJ
AD  - Joint Research Center of Liquid Biopsy in Guangdong, Hong kong, and Macao, 
      Zhuhai, China.
AD  - Zhuhai Sanmed Biotech Ltd., Zhuhai, China.
FAU - Zhang, Jun-Cheng
AU  - Zhang JC
AUID- ORCID: 0000-0001-6229-2473
AD  - Joint Research Center of Liquid Biopsy in Guangdong, Hong kong, and Macao, 
      Zhuhai, China.
AD  - Zhuhai Sanmed Biotech Ltd., Zhuhai, China.
FAU - Ma, Jing
AU  - Ma J
AD  - Department of Respiratory and Critical Care, Henan University Huaihe Hospital, 
      Kaifeng, China.
FAU - Zhou, Yan-Ling
AU  - Zhou YL
AD  - Joint Research Center of Liquid Biopsy in Guangdong, Hong kong, and Macao, 
      Zhuhai, China.
AD  - Zhuhai Sanmed Biotech Ltd., Zhuhai, China.
FAU - Fan, Xian-Jun
AU  - Fan XJ
AD  - Joint Research Center of Liquid Biopsy in Guangdong, Hong kong, and Macao, 
      Zhuhai, China.
AD  - Zhuhai Sanmed Biotech Ltd., Zhuhai, China.
FAU - Yue, Dong-Sheng
AU  - Yue DS
AD  - Department of Lung Cancer, Tianjin Lung Cancer Center, Tianjin Medical University 
      Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key 
      Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center 
      for Cancer, Tianjin, China.
FAU - Li, Chen-Guang
AU  - Li CG
AUID- ORCID: 0000-0002-7525-0595
AD  - Department of Lung Cancer, Tianjin Lung Cancer Center, Tianjin Medical University 
      Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key 
      Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center 
      for Cancer, Tianjin, China.
FAU - Zhang, Hua
AU  - Zhang H
AD  - Department of Lung Cancer, Tianjin Lung Cancer Center, Tianjin Medical University 
      Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key 
      Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center 
      for Cancer, Tianjin, China.
FAU - Ma, Yu-Chen
AU  - Ma YC
AD  - Department of Lung Cancer, Tianjin Lung Cancer Center, Tianjin Medical University 
      Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key 
      Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center 
      for Cancer, Tianjin, China.
FAU - Huo, Yan-Song
AU  - Huo YS
AD  - Department of Lung Cancer, Tianjin Lung Cancer Center, Tianjin Medical University 
      Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key 
      Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center 
      for Cancer, Tianjin, China.
FAU - Zhang, Zhen-Fa
AU  - Zhang ZF
AD  - Department of Lung Cancer, Tianjin Lung Cancer Center, Tianjin Medical University 
      Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key 
      Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center 
      for Cancer, Tianjin, China.
FAU - He, Shu-Yu
AU  - He SY
AD  - Joint Research Center of Liquid Biopsy in Guangdong, Hong kong, and Macao, 
      Zhuhai, China.
AD  - Zhuhai Sanmed Biotech Ltd., Zhuhai, China.
FAU - Wang, Chang-Li
AU  - Wang CL
AUID- ORCID: 0000-0003-1075-5071
AD  - Department of Lung Cancer, Tianjin Lung Cancer Center, Tianjin Medical University 
      Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key 
      Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center 
      for Cancer, Tianjin, China.
LA  - eng
GR  - 81672304/National Natural Science Foundation of China/International
GR  - 81772488/National Natural Science Foundation of China/International
GR  - 81772484/National Natural Science Foundation of China/International
GR  - 2019ZT08Y297/Program for Guangdong Introducing Innovative and Entrepreneurial 
      Teams/International
GR  - C1705/Tianjin Cancer Hospital Clinical Trial Project/International
GR  - 2016YFC0905500/National Key Research and Development Program of 
      China/International
GR  - 2016YFC0905501/National Key Research and Development Program of 
      China/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200928
PL  - Singapore
TA  - Thorac Cancer
JT  - Thoracic cancer
JID - 101531441
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Biomarkers, Tumor/*blood
MH  - Carcinoma, Non-Small-Cell Lung/*diagnosis/pathology
MH  - Early Detection of Cancer/*methods
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*diagnosis/pathology
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
PMC - PMC7606026
OTO - NOTNLM
OT  - Biomarker
OT  - circulating genetically abnormal cells
OT  - early detection
OT  - non-small-cell lung cancer
OT  - small nodules
EDAT- 2020/09/30 06:00
MHDA- 2021/08/07 06:00
PMCR- 2020/11/01
CRDT- 2020/09/29 05:42
PHST- 2020/07/23 00:00 [received]
PHST- 2020/08/21 00:00 [revised]
PHST- 2020/08/23 00:00 [accepted]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2021/08/07 06:00 [medline]
PHST- 2020/09/29 05:42 [entrez]
PHST- 2020/11/01 00:00 [pmc-release]
AID - TCA13654 [pii]
AID - 10.1111/1759-7714.13654 [doi]
PST - ppublish
SO  - Thorac Cancer. 2020 Nov;11(11):3234-3242. doi: 10.1111/1759-7714.13654. Epub 2020 
      Sep 28.